MARK SIRGO, PHARM.D.

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

BIOMERICA INC

Filing Date Source Excerpt
2016-09-28 Mark A. Sirgo, Pharm.D.,age 62, has served as President of BioDelivery Sciences International, Inc. ... He joined BDSI in August 2004 ... Dr. Sirgo served on the Board of Directors and as Chairman of the Compensation Committee of Salix Pharmaceuticals, Ltd. ... Mark Sirgo, Pharm.D. 62 2016 Director
2018-09-28 Mark Sirgo, Pharm.D., 64, Director, Chairman of Compensation Committee and Member of Audit and Nominating and Corporate Governance Committees. Total compensation for fiscal 2018 was $50,293.
2019-09-24 The following table sets forth the name and current age of each nominee for director, the year he or she was first elected a director and his or her position(s) with the Company. The Company does not pay a fee to any third party to identify potential nominees. The Board has not received recommended nominees from a stockholder.

Name

Age

Director Since

Positions Held

Mark Sirgo, Pharm. D.

65

2016

Director, Chairman of Compensation Committee and Member of Audit and Nominating and Corporate Governance Committees

...

Although not prohibited by the Company's Bylaws, directors receive no cash compensation for their services as directors, but they have been, and may in the future be, granted options to purchase the Company's securities which serves as compensation for their services. The compensation of directors is subject to review and adjustment from time to time by the Board of Directors.

     The following table presents the compensation of Non-Employee Directors for the fiscal year ended May 31, 2019.

- 10 -

DIRECTOR COMPENSATION

         Although not prohibited by the Company's Bylaws, directors receive no cash compensation for their services as directors, but they have been, and may in the future be, granted options to purchase the Company's securities which serves as compensation for their services. The compensation of directors is subject to review and adjustment from time to time by the Board of Directors.

     The following table presents the compensation of Non-Employee Directors for the fiscal year ended May 31, 2019.

- 10 -

DIRECTOR COMPENSATION

...

(1) All outside directors each received a 35,000 share stock option grant in fiscal 2019 except for Allen Barbieri, who received a 50,000 share stock option grant. The options were granted at the exercise price of $2.25 per share (market value on the date of grant). The grants for 35,000 were valued at $42,770 and the option for 50,000 was valued at $61,100 using the Black-Scholes options-pricing model (which uses assumptions for expected volatility, expected dividends, expected forfeiture rate, expected term and the risk-free interest rate).

Name

Fees Earned or Paid in Cash

($)

Stock Awards

($)

Option Awards

($)

Non-Equity Incentive Plan Compensation

($)

Change in Pension Value and Nonqualified Deferred Compensation Earnings

All Other Compensation

($)

Total

($)

Mark Sirgo, Pharm.D.

-0-

-0-

42,770

-0-

-0-

-0-

42,770

2020-09-25 Mark Sirgo, Pharm.D., 66, Director, Chairman of Compensation Committee and Member of Audit Committee. Compensation: $46,020 in fiscal 2020.

Data sourced from SEC filings. Last updated: 2025-07-01